| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -60,735 | -41,721 |
| Stock-based compensation expense | 11,135 | 7,581 |
| Depreciation of property and equipment | 86 | 59 |
| Accretion of discounts on short-term investments | 1,313 | 1,117 |
| Amortization of debt discount and costs | 171 | 58 |
| Loss on foreign currency exchange | -116 | -30 |
| Deferred income tax benefit | -681 | -681 |
| Accounts receivable | 301 | -223 |
| Prepaid expenses and other assets | 1,903 | 1,895 |
| Accounts payable | 4,593 | 640 |
| Accrued expenses and other liabilities | -1,962 | -2,064 |
| Income tax and r&d incentive receivables | -2,707 | -2,697 |
| Net cash used in operating activities | -48,087 | -36,190 |
| Proceeds from sales and maturities of short-term investments | 143,589 | 143,589 |
| Purchases of short-term investments | 196,894 | 47,573 |
| Purchases of property and equipment | 10 | 10 |
| Net cash used in investing activities | -53,315 | 96,006 |
| Payments of deferred offering costs | 298 | 298 |
| Proceeds from term loan | 15,000 | 15,000 |
| Payment for debt issuance costs | 726 | 404 |
| Proceeds from issuance of common stock in at-the-market offerings, net | 112,088 | 72,571 |
| Proceeds from issuance of common stock from employee stock purchase plan | 291 | 170 |
| Proceeds from exercises of stock options | 41 | 8 |
| Payments for tax withholding in share-based compensation | 684 | 684 |
| Net cash provided by (used in) financing activities | 125,712 | 86,363 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 24,310 | 146,179 |
| Cash and cash equivalents at beginning of period | 36,968 | - |
| Cash and cash equivalents at end of period | 61,278 | - |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)